Clinical trial NCT06652035: Possible Pharmacological Effect of Quercetin in the Management of Hyperuricemia - Results From Real-life Clinical Studies
Official title: Possible Pharmacological Effect of Quercetin in the Management of Hyperuricemia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hyperuricemia
Lead sponsor: Liaquat University of Medical & Health Sciences
Sponsor class: OTHER
Collaborators: name: The University of Urbino Carlo Bo, Italy
First posted: 2024-10-22
Enrollment: 161
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy participants visited the nutritional clinics during the COVID-19 pandemic for general health check up to improve their immunological protection against COVID-19 infection.

Brief summary: Quercetin, a natural flavonoid found in various fruits and vegetables, has gained attention for its potential role in managing hyperuricemia. Emerging evidence suggests that quercetin may reduce plasma uric acid levels by inhibiting xanthine oxidase, an enzyme responsible for uric acid production. Additionally, its anti-inflammatory and antioxidant properties could help mitigate the oxidative stress and inflammation associated with hyperuricemia. As a result, quercetin supplementation offers a promising avenue for therapeutic intervention in conditions like gout and other uric acid-related disorders.

Detailed description: In the present retrospective cross-sectional observational study, the investigators assessed the potential pharmacological effect of supplemental quercetin on the plasma uric acid levels of health adults. These participants visited nutritional clinics in Italy during the Coronavirus disease (COVID-19) pandemic for general health check-up in real-life to enhance their immune system with supplements aimed at providing additional protection against COVID-19 infection. The supplements, either quercetin or probiotic Streptococcus salivarius K12 (BLIS K12), were advised randomly to the participants for 90 days, tailored to individual needs and in the absence of any pre-defined criteria.

Eligibility criteria: Inclusion Criteria:

* Healthy adults
* BMI between 18.5 and 29.9 kg/m²
* Non-smoker
* Consumtion of less than 3 units of alcohol per day

Exclusion Criteria:

* - Plasma uric acid concentrations above 7 mg/dL
* Diagnosis of endocrinological, metabolic, oncological, neurological, or bowel inflammatory disease diseases, gout, kidney stones

Primary outcomes:
measure: Change in plasma uric acid level
timeFrame: 90 days
Secondary outcomes:
measure: Change in plasma cholesterol level
timeFrame: 90 days
measure: Change in plasma triglycerides level
timeFrame: 90 days
measure: Change in plasma glucose level
timeFrame: 90 days
measure: Change in plasma insulin level
timeFrame: 90 days
measure: Change in plasma creatine phosphokinase level
timeFrame: 90 days
measure: Change in alanine transaminase level
timeFrame: 90 days
measure: Change in aspartate aminotransferase level
timeFrame: 90 days
measure: Change in alkaline phosphatase level
timeFrame: 90 days
measure: Change in gamma-glutamyl transferase level
timeFrame: 90 days
measure: Change in bilirubin level
timeFrame: 90 days
measure: Incidence of side effects
timeFrame: 90 days
Other outcomes:
Locations:
city: Milano
country: Italy
facility: Dr. Buccomino Medical Clinic
Study officials:
References: